Oxford BioMedica PLC (OXBDF)

[marcusl2]

The University of Pennsylvania has licensed technologies involved in these trials to Novartis.

CLL patient goes into remission thanks to single CAR T cell
Case study provides clues that could help improve response rates
Date:
May 30, 2018
Source:
University of Pennsylvania School of Medicine
Summary:
Researchers say a patient treated for chronic lymphocytic leukemia (CLL) in 2013 went into remission because of a single CAR T cell and the cells it produced as it multiplied, and has stayed cancer free in the five years since, with CAR T cells still present in his immune system.

has stayed cancer free in the five years since, with CAR T cells still present in his immune system. The findings, published today in Nature, show the response is tied to where the CAR gene inserted itself into the patient's T cell DNA, a key factor that may help improve response rates to the therapy.

The American Cancer Society estimates there will be about 21,000 new CLL cases in 2018

HTTPS://www.sciencedaily.com/releases/2018/05/180530133022.htm